NEU 2.90% $19.86 neuren pharmaceuticals limited

Ann: Appendix 4C - quarterly, page-13

  1. 32 Posts.
    lightbulb Created with Sketch. 4
    For now being in the final month of the exclusivity period the market isn't convinced.. If this so called deal falls over the SP will most likely head south under $2 and confidence in the management team will majorly decrease as we go it alone for PH3 or try again with another partner.. (Guided by two principles – speed to market for the families affected by these debilitating conditions and value for our shareholders). Neither of these will be met if this deal falls over as it will take longer for us to go it alone and the risk and timeframe will be higher and longer for share holders..

    Love to be proven wrong but at some point you need to ask the question

    GLTA
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.